HOTLINE: Effective November 18, 2019

2009463 **Voltage-Gated Potassium Channel (VGKC) Antibody with Reflex to LGI1 and CASPR2 Screen and Titer, Serum** **VGKC R**

Reference Interval:

Test Number	Components	Reference Interval	
2004890	Voltage-Gated Potassium Channel (VGKC) Antibody, Serum	Negative	31 pmol/L or less
		Indeterminate	32-87 pmol/L
		Positive	88 pmol/L or greater
2009456	Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG with Reflex to Titer, Serum	Less than 1:10	
2009452	Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, Serum	Less than 1:10	

Interpretive Data: Voltage-Gated Potassium Channel (VGKC) antibodies are associated with neuromuscular weakness as found in neuromyotonia (also known as Issacs syndrome) and Morvan syndrome. VGKC antibodies are also associated with paraneoplastic neurological syndromes and limbic encephalitis; however, VGKC antibody-associated limbic encephalitis may be associated with antibodies to leucine-rich, glioma-inactivated 1 protein (LGIgi1) or contactin-associated protein-2 (CASPRaspr-2) instead of potassium channel antigens. A substantial number of VGKC-antibody positive cases are negative for LGI1 and CASPR-2 IgG autoantibodies, not all VGKC complex antigens are known. The clinical significance of this test can only be determined in conjunction with the patient's clinical history and related laboratory testing.

See Compliance Statement D: www.aruplab.com/CS

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.
Change the charting name for reflexed component 2009453, CASPR2 Ab IgG Screen by IFA to CASPR2 Ab IgG Screen by IFA, Serum.
Change the charting name for reflexed component 2009455 from CASPR2 Ab IgG Titer by IFA to CASPR2 Ab IgG Titer by IFA, Serum.
Change the charting name for reflexed component 2009457, LGI1 Ab IgG Screen by IFA to LGI1 Ab IgG Screen by IFA, Serum.
Change the charting name for reflexed component 2009459, LGI1 Ab IgG Titer by IFA to LGI1 Ab IgG Titer by IFA, Serum.